Benefit of uniQure's Huntington's gene therapy will be revealed 'in the fullness of time'

uniQure’s Huntington’s disease data were deemed “noisy and difficult to interpret” in June. While a new slice of interim results from the phase 1/2 trial may not help cut through the noise, the principal investigator says efficacy signals are “on the favorable side.”